Tagger Launches Q2 2023 Fashion Index Highlighting Top Brands in Influencer Marketing
7.9.2023 19:00:00 EEST | Business Wire | Press release
Tagger by Sprout Social, the global technology leader in making influencer marketing more intelligent, releases its Q2 Fashion Influencer Marketing Index today. The report highlights which fashion brands have seen the most success from influencer marketing and how others can tap into the insights behind millions of sponsored posts to drive sales and brand awareness.
Leveraging Tagger’s social intelligence engine, Signals, the report looks at overall platform performance for the second quarter. The Fashion Influencer Marketing Index shows an impressive 446,000 influencers posting 15.6 million times about fashion-related content, with Instagram leading the pack with the most posts. However, TikTok continues to drive results for brands, with the highest engagement rate of any platform at 2.18%.
“Our quarterly Fashion Report is one of our favorites to build within our Signals platform, as the industry always leads the way with new and innovative ways to work with influencers,” said Dave Dickman, Global Head of Sales and Services at Tagger by Sprout Social. “One of the more interesting points from this quarter’s report is the international reach of influencers and the ability for one person to catapult an entire city into the spotlight.”
Here are some key takeaways from the latest Fashion Influencer Marketing Report:
- Format is Everything: While TikTok’s engagement rate dropped 15%, it continues outperforming other platforms, including Instagram, by more than 120%.
- The Very Best: ZARA tops the list as the most-mentioned brand among influencers for the second quarter in a row, with Nike and Christian Dior as the second and third, respectively.
- Hashtags Rule the Day: This quarter’s report highlights which hashtags influencers use to better drive engagement, with #fashion and #ootd leading the way.
For Tagger’s full Q2 Fashion Influencer Marketing Report, visit: https://www.taggermedia.com/research/fashion-index-q2-2023
About the Data
The data referenced in the Q2 Fashion Influencer Marketing Report was collected via Tagger’s social intelligence engine, Signals. It looks at fashion-related posts from influencers globally across social platforms from April 1, 2023, through June 31, 2023.
About Tagger by Sprout Social
Tagger by Sprout Social is a global leader in revolutionizing how top brands and agencies harness data and analytics to drive creator and influencer marketing strategies. Trusted by global enterprises, Tagger is a disruptive SaaS solution that offers unparalleled expertise. Leveraging API partnerships with major social channels, Tagger connects millions of brand and influencer profiles to billions of social data points, offering the industry’s most robust social intelligence and actionable insights. Tagger’s platform provides powerful analytics, all-in-one capabilities, and strategic integrations for efficient campaign workflows. To learn more, visit www.taggermedia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907466701/en/
Contact information
Katie Huff
Trevelino/Keller
404.214.0722
khuff@trevelinokeller.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom